[HTML][HTML] Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review
HY Sun, MM Wagener, N Singh - American Journal of Transplantation, 2008 - Elsevier
The precise impact of valganciclovir as preventive therapy for cytomegalovirus (CMV) in
solid organ transplant (SOT) recipients is not fully defined. Data from studies using …
solid organ transplant (SOT) recipients is not fully defined. Data from studies using …
Prophylactic CMV therapy does not improve three‐yr patient and graft survival compared to preemptive therapy
J Werzowa, B Schwaiger, M Hecking… - Clinical …, 2015 - Wiley Online Library
Despite increasing evidence in favor of prophylactic valganciclovir treatment in kidney
transplant recipients for the prevention of cytomegalovirus (CMV) infection, the impact of …
transplant recipients for the prevention of cytomegalovirus (CMV) infection, the impact of …
LONG-TERM GANCICLOVIR PROPHYLAXIS FOR SUCCESSFUL PREVENTION OF PRIMARY CYTOMEGALOVIRUS (CMV) DISEASE IN CMV-SERONEGATIVE …
P Seu, DJ Winston, CD Holt, F Kaldas… - Transplantation, 1997 - journals.lww.com
Background. We conducted a trial of long-term ganciclovir prophylaxis for prevention of
primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with …
primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with …
Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients
KG Julian, E Shattahi, JE Burg, JP Boehmer - Transplantation proceedings, 2013 - Elsevier
We retrospectively assessed our center's experience with a protocol of low-dose (450 mg
once daily) valganciclovir administered for 3-6 months (median 5 months) in a cohort of of …
once daily) valganciclovir administered for 3-6 months (median 5 months) in a cohort of of …
Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants
FL Weng, AM Patel, R Wanchoo, Y Brahmbhatt… - …, 2007 - journals.lww.com
Background. The optimal regimen for prophylaxis of cytomegalovirus (CMV) disease after
kidney and/or pancreas transplantation remains unclear. We compared the effectiveness of …
kidney and/or pancreas transplantation remains unclear. We compared the effectiveness of …
High incidence of cytomegalovirus disease in D+/R− heart transplant recipients shortly after completion of 3 months of valganciclovir prophylaxis
S Gupta, JD Mitchell, DW Markham… - The Journal of heart and …, 2008 - Elsevier
BACKGROUND: Cytomegalovirus (CMV) infection remains a serious problem after heart
transplantation. Recipients with D+/R− CMV serostatus often receive prophylaxis with …
transplantation. Recipients with D+/R− CMV serostatus often receive prophylaxis with …
[HTML][HTML] Efficacy and safety of a lower-dose valganciclovir (valcyte) regimen for cytomegalovirus prophylaxis in kidney and pancreas transplant recipients
V Bhat, M McIntyre, T Meyers - Pharmacy and Therapeutics, 2010 - ncbi.nlm.nih.gov
Purpose: We evaluated the efficacy and safety of the current cytomegalovirus (CMV)
prophylaxis regimen used at Virginia Mason Medical Center in Seattle. Methods: A single …
prophylaxis regimen used at Virginia Mason Medical Center in Seattle. Methods: A single …
Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients
JT McKeen, DS Tsapepas, H Li… - Progress in …, 2015 - journals.sagepub.com
Context Cytomegalovirus (CMV) is an opportunistic infection that causes profound morbidity
and mortality after orthotopic liver transplant (OLT). The CMV immunoglobulin G …
and mortality after orthotopic liver transplant (OLT). The CMV immunoglobulin G …
Delayed occurrence of cytomegalovirus disease in organ transplant recipients receiving antiviral prophylaxis: are we winning the battle only to lose the war?
N Singh - European Journal of Clinical Microbiology and …, 2002 - search.proquest.com
CMV disease rate of 1% among all patients and a rate of 10% among those at risk for
primary CMV infection (seronegative recipients of seropositive allografts)[24]. However …
primary CMV infection (seronegative recipients of seropositive allografts)[24]. However …
Prophylactic Therapy With Valganciclovir in High-Risk (Cytomegalovirus D+/R−) Kidney Transplant Recipients: A Single-Center Experience
M Montejo, M Porto, O Carmon, S Zárraga… - Transplantation …, 2010 - Elsevier
BACKGROUND: A prospective study was performed in kidney transplant patients at risk of
developing cytomegalovirus (CMV) infection (CMV D+/R−). They were treated with …
developing cytomegalovirus (CMV) infection (CMV D+/R−). They were treated with …